Bionano Genomics reported unaudited preliminary financial results and commercial highlights for Q4 and FY 2025. The company's strategic initiatives in 2025 have reshaped its business model, enhanced its financial profile, and expanded the adoption of optical genome mapping (OGM) solutions. Key accomplishments in 2025, such as progress in reimbursement, software enhancements, and increased demand, set the stage for a promising start in 2026.
Financial Performance
In Q4 2025, Bionano anticipates total revenue in the range of $7.8-8.0 million, indicating a 2-4% decline year-over-year. For FY 2025, the estimated total revenue is $28.4-28.6 million, reflecting a 7-8% decrease compared to the previous year.
Product Metrics
During Q4 2025, Bionano sold 7,554 nanochannel array flowcells and installed 9 new OGM systems. In FY 2025, the company sold 30,171 flowcells and installed 32 new OGM systems, resulting in a year-end installed base of 387 systems.
Financial Position
As of December 31, 2025, Bionano held approximately $29.6 million in cash, cash equivalents, and securities, with $10.3 million subject to restrictions. The final financial statements for Q4 and FY 2025 are pending completion.
- Bionano's strategic efforts in 2025 have positioned the company for sustained growth and expanded market presence. The positive market response to OGM solutions and progress in reimbursement reflect the increasing acceptance and utilization of Bionano's technology.
Having executed a successful business model transition and achieved significant financial and operational milestones in 2025, Bionano Genomics is well-positioned for continued success in 2026.